CONMED Corporation Announces First Quarter 2026 Financial Results
CONMED reported Q1 sales of $317.0 million, down 1.3% year-over-year due to the exit of GI products, while Adjusted EPS came in at $0.89. Management raised its full-year 2026 organic revenue growth outlook to 5.0%–6.5% on a constant currency basis, up from 4.5%–6.0%, and updated total revenue guidance to $1.350B–$1.375B.
Key figures
- Eps
- 0.45
- Revenue
- $317.0 million
- Guidance
- FY26 organic constant currency revenue growth 5.0% to 6.5% (raised from 4.5% to 6.0%); reported revenue $1.350B-$1.375B; Adjusted EPS $4.30-$4.45 (reaffirmed)
- Revenue Yoy
- -1.3%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.